Technical Snapshots for These Biotech Stocks -- Merrimack Pharma, MannKind, GlycoMimetics, and Radius Health

Wednesday, June 28, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 28, 2017 /PRNewswire/ --

If you want a Stock Review on MACK, MNKD, GLYC or RDUS then come over to and sign up for your free customized report today. The Biotech industry includes companies that are engaged in the research and development of new drugs, medical devices, and procedures. It also includes the
manufacturing and marketing of drugs, as a result of direct research and development. Today, reviews Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), MannKind Corp. (NASDAQ: MNKD), GlycoMimetics Inc. (NASDAQ: GLYC), and Radius Health Inc. (NASDAQ: RDUS). Access's complimentary reports for today's stocks line-up at:

Merrimack Pharma 

Shares in Cambridge, Massachusetts headquartered Merrimack Pharmaceuticals Inc. saw a drop of 2.31%, ending Tuesday's trading session at $1.27. The stock recorded a trading volume of 1.65 million shares. The Company's shares are trading 35.07% below their 50-day moving average. Moreover, shares of Merrimack Pharma, which engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the US, have a Relative Strength Index (RSI) of 35.25.

On June 19th, 2017, Merrimack Pharma announced that it has enrolled the last patient in its ongoing CARRIE study - a Phase-2, double-blind, placebo-controlled, randomized trial evaluating MM-141 (istiratumab), in combination with standard of care in previously untreated patients with metastatic pancreatic cancer. MM-141 is a bispecific antibody targeting both the Insulin-Like-Growth-Factor-1-Receptor and the HER3 receptor, and is a potent inhibitor of the PI3K/AKT/mTOR signaling pathway. Visit us today and access your complete report on MACK for free at:


Valencia, California headquartered MannKind Corp.'s stock rose 3.31%, closing the day at $1.56 with a total trading volume of 1.41 million shares. The Company's shares have advanced 2.63% in the past month. The stock is trading 23.56% above its 50-day moving average. Additionally, shares of MannKind, which focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the US, have an RSI of 58.51.

On May 31st, 2017, MannKind and BIOMM S.A. announced that they have entered into a supply and distribution agreement for the commercialization of Afrezza® (insulin human) Inhalation Powder in Brazil. Under the supply and distribution agreement, the latter will be responsible for preparing and filing the necessary applications for regulatory approval of Afrezza, including from the Agência Nacional de Vigilância Sanitária and, with respect to pricing matters, from the Camara de Regulação de Mercado de Medicamentos.  The complimentary research report on MNKD can be accessed at:


On Tuesday, shares in Rockville, Maryland headquartered GlycoMimetics Inc. recorded a trading volume of 860,610 shares. The stock ended the day 8.41% lower at $11.55. The Company's shares have surged 106.25% in the previous three months and 89.34% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 33.19% and 69.60%, respectively. Furthermore, shares of GlycoMimetics, which focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the US, have an RSI of 52.32.

On June 12th, 2017, GlycoMimetics announced the appointment of Patricia S. Andrews, CEO and Director of Boston Biomedical, Inc., to its Board of Directors. Ms. Andrews was named CEO of Boston Biomedical in April 2017. Register for free on and download the research report on GLYC at:

Radius Health 

Waltham, Massachusetts headquartered Radius Health Inc.'s stock dropped 3.77%, finishing yesterday's session at $44.90 with a total trading volume of 771,482 shares. The Company's shares have advanced 28.54% in the last one month, 16.41% in the previous three months, and 18.06% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 18.27% and 3.04%, respectively. Additionally, shares of Radius Health, which develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the US, have an RSI of 64.68.

On June 04th, 2017, Radius Health announced positive data from a fully enrolled ongoing Phase-1 study of elacestrant (RAD1901), an oral selective estrogen receptor degrader, in patients with estrogen receptor positive breast cancer. Of forty enrolled patients, 22 met the RECIST measurable disease criteria at baseline, and there were five confirmed partial responses in this group. Elacestrant was well tolerated, with the most common adverse events being low-grade nausea and dyspepsia. Get free access to your research report on RDUS at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store